Amneal to Acquire Kashiv BioSciences for $763M Upfront, Up to $1.1B Total, and Raises FY26 Guidance

summarizeSummary

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $762.9 million upfront, with potential for up to $1.1 billion including earnouts, to build a global biosimilars platform. The company also reported strong preliminary Q1 2026 results and raised its full-year guidance.

check_boxKey Events · M&A and Partnerships · AMRX

• Definitive Acquisition Agreement

  Amneal Pharmaceuticals entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC. The transaction includes $375 million in cash and 28,942,108 shares of Class A common stock, valued at approximately $387.9 million based on the current stock price. This totals $762.9 million in upfront consideration.

• Significant Potential Earnouts

  The acquisition also includes potential contingent payments of up to $350 million upon the achievement of certain regulatory milestones for designated product candidates, plus potential contingent royalty payments over a 12-year period, bringing the total potential deal value to over $1.1 billion.

• Strategic Rationale for Biosimilars

  The acquisition is a strategic move to establish a scaled, fully integrated global biosimilars platform, positioning Amneal to capitalize on a projected $300 billion+ global biologics loss-of-exclusivity opportunity over the next decade. It is expected to accelerate growth and diversify Amneal's long-term profile.

• Preliminary Q1 2026 Financial Results

  Amneal reported strong preliminary Q1 2026 results, with consolidated net revenue of $723 million (up 4% year-over-year), net income of $78 million (up 217%), Adjusted EBITDA of $202 million (up 19%), and Adjusted diluted EPS of $0.27 (up 29%).

auto_awesomeAnalysis · AMRX · Life Sciences

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences, a strategic move to establish a fully integrated global biosimilars platform. The acquisition is valued at $375 million in cash and approximately $387.9 million in stock consideration (28,942,108 shares at $13.41/share), totaling $762.9 million upfront. Additionally, sellers are eligible for up to $350 million in contingent regulatory milestone payments and potential royalties, bringing the total potential value to over $1.1 billion. This transaction is highly strategic, aiming to capitalize on a projected $300 billion+ global biologics market opportunity over the next decade and diversify Amneal's long-term growth profile. The stock consideration represents approximately 9.07% dilution based on current outstanding shares. Concurrently, Amneal reported strong preliminary Q1 2026 results, with consolidated net revenue up 4% to $723 million and net income up 217% to $78 million. The company also raised its full-year 2026 guidance for Adjusted EBITDA, Adjusted diluted EPS, and Operating cash flow, signaling robust standalone performance. The combination of a significant strategic acquisition and positive financial performance is a strong market signal.